Wedbush Has Positive Outlook for Chimerix FY2025 Earnings

Chimerix, Inc. (NASDAQ:CMRXFree Report) – Equities researchers at Wedbush upped their FY2025 earnings per share estimates for Chimerix in a note issued to investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings per share of ($0.03) for the year, up from their prior forecast of ($1.09). Wedbush has a “Outperform” rating and a $7.00 price objective on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix’s Q4 2025 earnings at $0.74 EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at $0.02 EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Chimerix in a research report on Tuesday.

Read Our Latest Analysis on Chimerix

Chimerix Trading Up 1.8 %

Shares of Chimerix stock opened at $5.17 on Thursday. The firm has a market capitalization of $464.99 million, a PE ratio of -5.50 and a beta of 0.35. Chimerix has a 12 month low of $0.75 and a 12 month high of $5.53. The business’s 50-day moving average price is $3.72 and its 200-day moving average price is $1.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new stake in Chimerix in the fourth quarter worth $130,000. Two Sigma Investments LP grew its position in shares of Chimerix by 309.1% in the 4th quarter. Two Sigma Investments LP now owns 101,156 shares of the biopharmaceutical company’s stock worth $352,000 after buying an additional 76,430 shares during the period. OMERS ADMINISTRATION Corp bought a new position in shares of Chimerix in the 4th quarter worth about $535,000. Millennium Management LLC lifted its position in Chimerix by 6.8% during the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after acquiring an additional 161,795 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new stake in Chimerix during the fourth quarter worth about $13,124,000. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Insider Activity at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 20,760 shares of company stock worth $91,175 over the last quarter. Corporate insiders own 13.10% of the company’s stock.

Chimerix Company Profile

(Get Free Report)

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

Featured Articles

Earnings History and Estimates for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.